1st Quarter - Report

AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS for AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

Firm
Client
Income
—
Expenses
$250,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Labor-Health and Human Services Appropriations seeking Food and Drug Administration funding.

LobbyistCovered position, as disclosed
NICHOLAS GENTILE —
JOSEPH M HILL —
BRIAN M MEYER —
KASEY THOMPSON —
CHRISTOPHER J TOPOLESKI —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Government Accountability Office (GAO); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Federal Trade Commission (FTC); SENATE

Medicare/Medicaid MMM

Communication with Centers for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, and annual payment updates. Support for HR 4190, a bill that would amend Title 18 of the Social Security Act to provide for coverage under the Medicare Program of pharmacist services.

LobbyistCovered position, as disclosed
NICHOLAS GENTILE —
JOSEPH M HILL —
BRIAN M MEYER —
KASEY THOMPSON —
CHRISTOPHER J TOPOLESKI —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Federal Trade Commission (FTC); Government Accountability Office (GAO)

Bills named: H.R. 4190 (113th)

Pharmacy PHA

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Contact concerning HRSA oversight of 340B drug discount program. Communication with the GAO on compounding. Contact concerning the Drug Quality and Security Act, H.R. 3204, all titles. Communication with the FDA on labeling of generic medications and drugs containing salts. Communication with FTCon biosimilars. Support for H.R. 3742, all titles, theAntibiotic Development to Advance patient Treatment Act.

LobbyistCovered position, as disclosed
NICHOLAS GENTILE —
JOSEPH M HILL —
BRIAN M MEYER —
KASEY THOMPSON —
CHRISTOPHER J TOPOLESKI —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Federal Trade Commission (FTC); Centers For Medicare and Medicaid Services (CMS); Government Accountability Office (GAO); Food & Drug Administration (FDA)

Bills named: H.R. 3742 (113th), H.R. 3204 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.